Current Status and Prospects of Targeted Therapy for Osteosarcoma
Zunguo Hu,
Shuang Wen,
Zijun Huo,
Qing Wang,
Jiantao Zhao,
Zihao Wang,
Yanchun Chen,
Lingyun Zhang,
Fenghua Zhou,
Zhangyu Guo,
Huancai Liu,
Shuanhu Zhou
Affiliations
Zunguo Hu
Department of Joint Surgery, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261061, China
Shuang Wen
Department of Joint Surgery, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261061, China
Zijun Huo
Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China
Qing Wang
Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China
Jiantao Zhao
Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China
Zihao Wang
Department of Joint Surgery, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261061, China
Yanchun Chen
Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China
Lingyun Zhang
Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China
Fenghua Zhou
Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China
Zhangyu Guo
Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China
Huancai Liu
Department of Joint Surgery, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261061, China
Shuanhu Zhou
Department of Orthopedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS prognosis is poor, and improving the survival of OS patients remains a challenge. Current treatment methods such as surgical approaches, chemotherapeutic drugs, and immunotherapeutic drugs remain ineffective. As research progresses, targeted therapy is gradually becoming irreplaceable. In this review, several treatment modalities for osteosarcoma, such as surgery, chemotherapy, and immunotherapy, are briefly described, followed by a discussion of targeted therapy, the important targets, and new technologies for osteosarcoma treatment.
